Medical journal The Lancet publicly acknowledged Tuesday that a massive study on hydroxychloroquine that raised serious health concerns about the anti-malaria drug was potentially flawed.
The Lancet issued an "expression of concern" on a study it published last month of nearly 100,000 patients that tied hydroxychloroquine and chloroquine to a higher risk of death in hospitalized patients with the coronavirus.
The journal said that "serious scientific questions have been brought to our attention" about the study and that the authors have commissioned an independent review of the data.
[...]
Following the publication of the study, numerous scientists around the world raised concerns with what they said was inconsistent data in the report.
The study's authors, led by Mandeep Mehra of Harvard Medical School, have repeatedly declined to release their underlying data, despite signing a pledge to share information on the coronavirus.
Last week, the study’s research team corrected some of its data but said its conclusions remained the same.
The Hill
UPDATE:
The World Health Organization (WHO) will resume a clinical trial to study the effects of the anti-malaria drug touted by President Trump as a treatment for COVID-19 after pausing it due to safety concerns, the organization said Wednesday.
Enrollment in the hydroxychloroquine arm of the Solidarity Trial was temporarily paused last week after an article in The Lancet medical journal warned about the safety of the drug.
[...]
In the U.S., a 2,000-person trial launched by the National Institute of Allergy and Infectious Diseases is also underway.
The Hill
No comments:
Post a Comment